SEC FORM 3

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Danilkovitch Alla

(Last)

(First)

(Middle)

C/O OSIRIS THERAPEUTICS, INC.

7015 ALBERT EINSTEIN DRIVE

(Street)

COLUMBIA

21046-1707

(City)

(State)

(Zip)

2. Date of Event Requiring Statement (Month/Day/Year)
04/09/2015

3. Issuer Name and Ticker or Trading Symbol
OSIRIS THERAPEUTICS, INC. [ OSIR ]

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	10% Owner
X	Officer (give title below)	Other (specify below)
	Chief Scientific Officer

5. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)
Common Stock	5,375	D

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
1. Title of Derivative Security (Instr. 4)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
Non-Qualified Stock Option (right to buy)	12/01/2006⁽¹⁾	12/01/2015	Common Stock	5,000	$0.4	D
Incentive Stock Option (right to buy)	07/26/2008⁽¹⁾	07/26/2017	Common Stock	3,000	$12.5	D
Incentive Stock Option (right to buy)	10/02/2009⁽¹⁾	10/02/2018	Common Stock	3,000	$17.1	D
Incentive Stock Option	03/12/2011⁽¹⁾	03/12/2020	Common Stock	8,000	$7.74	D
Incentive Stock Option (right to buy)	05/27/2011⁽¹⁾	05/27/2020	Common Stock	5,000	$6.46	D
Incentive Stock Option (right to buy)	02/14/2012⁽¹⁾	02/14/2021	Common Stock	9,000	$7.13	D
Incentive Stock Option (right to buy)	03/23/2013⁽²⁾	03/23/2022	Common Stock	10,000	$5.08	D
Incentive Stock Option (right to buy)	02/12/2013⁽³⁾	02/12/2023	Common Stock	10,000	$7.73	D
Non-Qualified Stock Option (right to buy)	05/06/2015⁽⁴⁾	05/06/2024	Common Stock	1,436	$14	D
Incentive Stock Option (right to buy)	05/06/2015⁽⁴⁾	05/06/2024	Common Stock	18,564	$14	D
Non-Qualified Stock Option (right to buy)	03/06/2016⁽⁵⁾	03/06/2025	Common Stock	17,356	$18.4	D
Incentive Stock Option (right to buy)	03/06/2016⁽⁵⁾	03/06/2025	Common Stock	7,644	$18.4	D

Explanation of Responses:

1. The option to purchase shares of Osiris Therapeutics, Inc. common stock is immediately exercisable with respect to the underlying shares as of the date of this Form 3.

2. The option to purchase 10,000 shares of Osiris Therapeutics, Inc. common stock is immediately exercisable with respect to 7,500 of the underlying shares and the remaining 2,500 options shall become exercisable on March 23, 2016, assuming the Reporting Person continues to be employed by the Registrant on the vesting date.

3. The option to purchase 10,000 shares of Osiris Therapeutics, Inc. common stock is immediately exercisable with respect to 5,000 of the underlying shares and the remaining 5,000 options shall become vested, 2,500 on February 12, 2016 and 2,500 on February 12, 2017, assuming the Reporting Person continues to be employed by the Registrant on the vesting dates.

4. The option to purchase 20,000 shares of Osiris Therapeutics, Inc. common stock shall become exercisable with respect to the underlying shares as to 25% on each May 6, 2015, 2016, 2017 and 2018, assuming the Reporting Person continues to be employed by the Registrant on the vesting date.

5. The option to purchase 25,000 shares of Osiris Therapeutics, Inc. common stock shall become exercisable with respect to the underlying shares as to 25% on each March 6, 2016, 2017, 2018 and 2019, assuming the Reporting Perosn continues to be employed by the Registrant on the vesting date

	Alla Danilkovitch	04/09/2015
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.